CardioDynamics introduces its BioZ System at the 46th Annual Scientific Session of the American College of Cardiology.

SAN DIEGO--(BUSINESS WIRE)--March 19, 1997--CardioDynamics International Corp. (OTC:CRDY) Wednesday announced the worldwide introduction of its BioZ (TM) System at the 46th Annual Scientific Session of the American College of Cardiology (ACC) in Anaheim, Calif.

The BioZ (TM) System is simultaneously being introduced at the MEDICA-Netherlands Meeting (March 18-21, 1997) in Utrecht, Netherlands with attendees from Germany, Belgium, Luxembourg and Netherlands, and later this month at the Japan Circulatory Congress in Tokyo.

The BioZ (TM) System, a noninvasive digital heart monitoring device, uses Thoracic Electrical Bioimpedance (TEB) technology to obtain continuous data for heart monitoring, which is typically only available through a time-consuming, costly, potentially dangerous invasive procedure called "right-heart catheterization." TEB monitoring permits patients to receive treatment in a safe, efficient and cost-effective manner.

Richard E. Otto, president and chief executive officer of CardioDynamics, stated, "The 46th Annual Scientific Session of the ACC provided a tremendous opportunity to showcase our BioZ (TM) System to leading cardiologists in the United States. There has been significant interest for our technology from several hundred physicians and health care personnel in the first two days of the conference, and we have received a similar level of interest from the medical community in attendance at MEDICA conference in the Netherlands.

"To date, we have received over $1.0 million in initial orders for the BioZ (TM) System from distributors, and we are pleased with the continued demand for our technology."

Scripps Clinic and Research Foundation presented research data at the ACC Conference from a study utilizing the company's BioZ (TM) System as an adjunct to dobutamine echocardiography. Dobutamine is given intravenously in small, increasing increments during an echocardiogram to produce images of the heart, which are used to determine the heart's pumping capacity, state of contractility and cardiac reserve.

Initial results of the study show a predictive trend in the TEB contractility and cardiac index parameters when compared to dobutamine echocardiography results. A multicenter study is planned to assess the value of the BioZ (TM) System transthoracic bioimpedence as an adjunct to echocardiography during pharmacologic stress testing.

CardioDynamics International develops and markets proprietary, state-of-the-art, noninvasive hemodynamic monitoring equipment for hospital and clinical use. -0- NOTE: Sentences in this document containing verbs such as "plan," "intend," "anticipate," etc. and/or future-tense or conditional constructions ("will," "may," "could," "should," etc.) constitute forward-looking statements that involve risks and uncertainties. Items contemplating, or making assumptions about, actual or potential future sales, trends or operating results also constitute such forward-looking statements.

These statements are only predictions and actual results could differ materially.

Among the factors that could cause the company's actual results to differ materially from those indicated in any such forward-looking statements are: (i) sole dependence on the newly introduced BioZ (TM) System and related products, (ii) the current general acceptance in the medical community of invasive procedures such as right-heart catheterization and the lack of general acceptance of thoracic electrical biompedance, (iii) the timing and results of multicenter and other clinical trials of the BioZ (TM) System, (iv) competition from Baxter Health Care Corp., the maker of the Swan-Ganz (TM) RHC device, (v) various problems charactertistic of companies just emerging from the development stage, and (vi) dependence on third parties for manufacturing and distribution; as well as other risks detailed in the company's annual report on Form 10-KSB for the fiscal year ended Nov. 30, 1996 and other risks identified from time to time in the company's other materials filed with the Securities and Exchange Commission.

The company does not undertake to update the disclosures contained in this document.

CONTACT: CardioDynamics International Corp., San Diego

Richard E. Otto/Rhonda F. Pederson, 800/778-4825

or

Lippert/Heilshorn & Associates Inc., New York

Keith Lippert/Evan D. Smith, 212/838-3777

(investor relations)